Interestingly, preferential targeting of mTORC2 versus mTORC1 reduced breast cancer cell motility and survival in culture and in vivo [18, 49], and Rictor knockdown suppressed anchorage-independent growth of MCF7 breast tumor cells [50]. Here, RICTOR is linked to breast neoplasm.